Table 3: Response to T-DM1.
Response | Number of patients (%) |
Complete response | 3 (5%) |
Partial response | 19 (30%) |
Long stable disease (≥ 6 months) | 9 (14%) |
Stable disease (< 6 months) | 9 (14%) |
Progressive disease | 21 (33%) |
Not evaluable | 2 (3%) |
Response rate | 35% |
Clinical benefit rate | 49% |
Median time to treatment failure, months (range) | 4.0 (0.7-26.0) |